Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Short term Debt (2025)

Adma Biologics' Short term Debt history spans 1 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Short term Debt changed N/A year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, changed N/A, while the annual FY2025 figure was $2.8 million, N/A changed from the prior year.
  • Short term Debt reached $2.8 million in Q4 2025 per ADMA's latest filing, up from $2.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $2.8 million in Q4 2025 to a low of $2.3 million in Q3 2025.